Bile acids in liver and gastrointestinal cancer

Bile acids (BAs) are cholesterol-derived metabolites synthesized by hepatocytes and secreted in bile to follow an inter-organ transit to the intestine, where they facilitate fat digestion and the absorption of lipids and liposoluble vitamins. Traditionally considered mere end products of cholesterol...

Descripción completa

Detalles Bibliográficos
Autores: Monte, Maria J., Fàbrega, Laura, Romero, Marta R., Temprano, Alvaro G., Kaplowitz, Neil, García-Ruiz, Carmen, Marin, Jose J. G., Fernández-Checa, José C.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/403693
Acceso en línea:http://hdl.handle.net/10261/403693
https://api.elsevier.com/content/abstract/scopus_id/105015428461
Access Level:acceso abierto
Palabra clave:Bile acids
Cholesterol
Gastrointestinal cancers
Liver cancer
id ES_8da67358d2e750d1c8e9a0afe1bfbf6d
oai_identifier_str oai:digital.csic.es:10261/403693
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Bile acids in liver and gastrointestinal cancer
title Bile acids in liver and gastrointestinal cancer
spellingShingle Bile acids in liver and gastrointestinal cancer
Monte, Maria J.
Bile acids
Cholesterol
Gastrointestinal cancers
Liver cancer
title_short Bile acids in liver and gastrointestinal cancer
title_full Bile acids in liver and gastrointestinal cancer
title_fullStr Bile acids in liver and gastrointestinal cancer
title_full_unstemmed Bile acids in liver and gastrointestinal cancer
title_sort Bile acids in liver and gastrointestinal cancer
dc.creator.none.fl_str_mv Monte, Maria J.
Fàbrega, Laura
Romero, Marta R.
Temprano, Alvaro G.
Kaplowitz, Neil
García-Ruiz, Carmen
Marin, Jose J. G.
Fernández-Checa, José C.
author Monte, Maria J.
author_facet Monte, Maria J.
Fàbrega, Laura
Romero, Marta R.
Temprano, Alvaro G.
Kaplowitz, Neil
García-Ruiz, Carmen
Marin, Jose J. G.
Fernández-Checa, José C.
author_role author
author2 Fàbrega, Laura
Romero, Marta R.
Temprano, Alvaro G.
Kaplowitz, Neil
García-Ruiz, Carmen
Marin, Jose J. G.
Fernández-Checa, José C.
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Agencia Estatal de Investigación (España)
Ministerio de Ciencia, Innovación y Universidades (España)
Ministerio de Ciencia e Innovación (España)
Instituto de Salud Carlos III
European Commission
Junta de Castilla y León
Generalitat de Catalunya
Fernández-Checa, José C. [0000-0003-3422-2990]
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Bile acids
Cholesterol
Gastrointestinal cancers
Liver cancer
topic Bile acids
Cholesterol
Gastrointestinal cancers
Liver cancer
description Bile acids (BAs) are cholesterol-derived metabolites synthesized by hepatocytes and secreted in bile to follow an inter-organ transit to the intestine, where they facilitate fat digestion and the absorption of lipids and liposoluble vitamins. Traditionally considered mere end products of cholesterol catabolism, they are now acknowledged to play intricate roles in regulating intermediary metabolism by controlling the expression of crucial genes. Additionally, they exert a significant impact on inflammation, cytotoxicity, and carcinogenesis. Moreover, BAs have a critical impact on the crosstalk between gut microbiota and host physiology, which affects the progression of liver and gastrointestinal cancers. Clinical data and results from studies of animal models support the involvement of BAs in the development of hepatocellular carcinoma, cholangiocarcinoma, colorectal adenocarcinoma, and pancreatic cancer. On the other hand, BAs and their derivatives have been proposed as pharmacological tools in strategies to restore abnormal hepatobiliary function and target cytostatic agents to cancers of the enterohepatic circuit. In the present review, we summarize basic concepts of BA physiology and regulation, as well as new advances in this expanding field of renewed interest for cancer biology, lending further support for the key role of BAs in liver and gastrointestinal cancer.
publishDate 2025
dc.date.none.fl_str_mv 2025
2025
2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/403693
https://api.elsevier.com/content/abstract/scopus_id/105015428461
url http://hdl.handle.net/10261/403693
https://api.elsevier.com/content/abstract/scopus_id/105015428461
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv #PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2019-111669RB-I00
info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2020-115055RB-I00
info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/PID2022-142956OB-I00
info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/PID2022-140210OB-I00
info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/PID2023-148803OB-I00
info:eu-repo/grantAgreement/EC/HE/101095679
https://doi.org/10.1016/j.semcancer.2025.09.002
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier BV
publisher.none.fl_str_mv Elsevier BV
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869413063683211264
spelling Bile acids in liver and gastrointestinal cancerMonte, Maria J.Fàbrega, LauraRomero, Marta R.Temprano, Alvaro G.Kaplowitz, NeilGarcía-Ruiz, CarmenMarin, Jose J. G.Fernández-Checa, José C.Bile acidsCholesterolGastrointestinal cancersLiver cancerBile acids (BAs) are cholesterol-derived metabolites synthesized by hepatocytes and secreted in bile to follow an inter-organ transit to the intestine, where they facilitate fat digestion and the absorption of lipids and liposoluble vitamins. Traditionally considered mere end products of cholesterol catabolism, they are now acknowledged to play intricate roles in regulating intermediary metabolism by controlling the expression of crucial genes. Additionally, they exert a significant impact on inflammation, cytotoxicity, and carcinogenesis. Moreover, BAs have a critical impact on the crosstalk between gut microbiota and host physiology, which affects the progression of liver and gastrointestinal cancers. Clinical data and results from studies of animal models support the involvement of BAs in the development of hepatocellular carcinoma, cholangiocarcinoma, colorectal adenocarcinoma, and pancreatic cancer. On the other hand, BAs and their derivatives have been proposed as pharmacological tools in strategies to restore abnormal hepatobiliary function and target cytostatic agents to cancers of the enterohepatic circuit. In the present review, we summarize basic concepts of BA physiology and regulation, as well as new advances in this expanding field of renewed interest for cancer biology, lending further support for the key role of BAs in liver and gastrointestinal cancer.We acknowledge the support from grants PID2019-111669RB-100, PID2020-115055RB-I00, PID2022-142956OB-100, PID2022-140210OB-100, PID2023-1488030B-100, 2024AEP053; 2023AEPP068 and 2020AEPP145 from Plan Nacional de I+D funded by the Agencia Estatal de Investigación (AEI); Plan Nacional sobre Drogas grant 2024; and PI22/00526 from the Fondo de Investigaciones Sanitarias, Instituto Salud Carlos III, Spain co-funded by European Regional Development Fund/European Social Fund, Junta Castilla y Leon (SA113/P23) and from the CIBEREHD; as well as support from AGAUR of the Generalitat de Catalunya SGR-2021–00491, and funding from the European Horizon´s research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679, as well as support from National Cancer Institute PO1 CA281819–01A1 from the NIH. L.F. is supported by a Jaume Bosch contract from the CIBEREHD, and she is a PhD student of the Biomedicine Program of the University of Barcelona, Spain.Peer reviewedElsevier BVAgencia Estatal de Investigación (España)Ministerio de Ciencia, Innovación y Universidades (España)Ministerio de Ciencia e Innovación (España)Instituto de Salud Carlos IIIEuropean CommissionJunta de Castilla y LeónGeneralitat de CatalunyaFernández-Checa, José C. [0000-0003-3422-2990]Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202520252025info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/403693https://api.elsevier.com/content/abstract/scopus_id/105015428461reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Inglés#PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE#info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2019-111669RB-I00info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2020-115055RB-I00info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/PID2022-142956OB-I00info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/PID2022-140210OB-I00info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/PID2023-148803OB-I00info:eu-repo/grantAgreement/EC/HE/101095679https://doi.org/10.1016/j.semcancer.2025.09.002Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/4036932026-05-22T06:33:51Z
score 15.811543

Similares en LA Referencia